Neoprobe Corporation (OTCBB:Â NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that its Senior Vice President and CFO, Brent Larson, will present at the upcoming LifeTech Capital 1st Annual Miami Medical Investors Conference on November 12, 2010, at 9:00 am ET. The conference is being held at the JW Marriott Marquis in Miami.
Neoprobe expects to participate in other conferences over the coming months and will update the investment community as appropriate when more details are available.
Neoprobe executives will also discuss the development activities for both the RIGS® and Lymphoseek® product initiatives during the third quarter earnings conference call scheduled for 4:30 PM ET, on Wednesday, November 10, 2010.
| Â | |||||||||||||||
| Conference Call Information | |||||||||||||||
| TO PARTICIPATE LIVE: | Â | Â | Â | Â | Â | Â | TO LISTEN TO A REPLAY: | ||||||||
| Date: | Â | Â | Â | Nov 10, 2010 | Â | Â | Â | Â | Â | Â | Available until: | Â | Â | Â | Nov 24, 2010 |
| Time: | 4:30 PM ET | Toll-free (U.S.) Dial in # : | 877-660-6853 | ||||||||||||
| International Dial in # : | 201-612-7415 | ||||||||||||||
| Toll-free (U.S.) Dial in # : | 877-407-8033 | Replay Passcodes (both | |||||||||||||
| International Dial in # : | 201-689-8033 | required for playback): | |||||||||||||
| Account # : | 286 | ||||||||||||||
| Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Conference ID # : | Â | Â | Â | 360421 |
About Neoprobe Corporation
Neoprobe Corporation (OTCBB: NEOP) is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScan™. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com.
Contacts:
Neoprobe Corporation
Brent Larson, 614-822-2330
Sr.
Vice President & CFO
or
Makovsky + Company
Gene
Marbach, 212-508-9645
